Form 4 for LGND LIGAND PHARMACEUTICALS INC
Accepted 2025-03-06 00:00:00 ET · period of report 2025-03-04 · accession 0002001011-25-000014 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-03-06 | 2025-03-04 | LGND | Davis Todd C | CEO, Dir | A - Grant | $0.00 | +21.4K | 151.7K | +16% | $0 |
| D | 2025-03-06 | 2025-03-04 | LGND | Davis Todd C | CEO, Dir | A - Grant | $0.00 | +93.5K | 93.5K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-03-04 | A | A | 21,382 | $0.00 | 151,724 | D | — | — | (F1) Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest over three years, in three substantially equal annual installments on February 15, 2026; February 15, 2027; and February 15, 2028, subject to the Reporting Person's continued service to the Issuer through each such vesting date. |
| 2 | Derivative | Employee Stock Option (right to buy) | 2025-03-04 | A | A | 93,476 | $0.00 | 93,476 | D | $115.26 · — to 2035-03-04 | 93,476 Common Stock | (F2) The Stock Option grant vests and is exercisable as to 12.5% of the underlying shares 6 months after the grant date, and in 42 substantially equal monthly installments thereafter. |